Adults with both peripheral artery disease (PAD) and hypertension face elevated cardiovascular risk. Achieving blood pressure control in this population is a priority to reduce the risk of stroke, myocardial infarction, heart failure, and cardiovascular death.
Effective blood pressure management targets a specific threshold in this population to optimise major adverse cardiovascular event (MACE) reduction.
Evidence supports a particular class of antihypertensive agent as the preferred first-line choice for adults with PAD and hypertension, based on demonstrated cardiovascular benefit. The full selection criteria, clinical decision pathway, and sequencing are in the structured protocol.
DOI: 10.1161/CIR.0000000000001356
Treatment of hypertension to a goal BP of <130/80 mm Hg in adults with PAD is optimal to reduce the risk of MACE, including stroke, MI, HF, and cardiovascular death.
Although no single antihypertensive medication appears to be more effective at treating hypertension in adults with PAD, cardiovascular benefits are shown with the use of ACEi or ARB, and these agents should be first line for adults with PAD and hypertension.
View source ↗